)
Per Lindell
Per Lindell is a seasoned life sciences executive and management consultant with over 25 years of international experience spanning the U.S., Europe, Japan, and Australia. As President of Panther Therapeutics, he brings a uniquely broad and deep expertise in biopharma strategy, operations, and innovation, combining hands-on executive leadership with world-class consulting experience.
Per holds a Doctor of Science in Biochemical Engineering with a minor in Management from MIT and a Master of Science in Chemical Engineering from the Royal Institute of Technology in Sweden. A Fulbright Scholar and member of leading consultant networks such as Umbrex, BiotechExec, and Alacrita, he has worked across the value chain of drug development—from early discovery through manufacturing, clinical development, and commercialization.
His consulting background includes tenure at Boston Consulting Group, Arthur D. Little, and IBM. He has held senior leadership roles at Big Pharma and biotech companies including Pharmacia and BASF Pharma, and has served as acting COO or CEO for multiple biotech ventures. His strategic advisory work includes supporting major licensing and M&A deals, clinical trial planning, university tech transfer, and guiding companies through Series A/B funding rounds, Nasdaq listings, and PIPEs.
Per’s therapeutic expertise spans small molecules, peptides, monoclonal antibodies, gene and cell therapies (especially AAV), and RNA-based therapeutics. He has contributed to programs in obesity, oncology, GI, infectious disease, CNS, immunology, ophthalmology, cardiovascular, and respiratory indications. He also has experience managing biologics and gene therapy manufacturing operations and is well-versed in the application of AI and machine learning for drug discovery.
An experienced negotiator and strategic planner, Per has advised CEOs of large pharmaceutical companies and contributed to the development and launch of numerous high-impact therapeutics. He has also taught graduate-level courses at MIT and continues to mentor companies through periods of rapid growth and transformation.